We designed a subcutaneous tumor model by knocking out SOX9 in CRC cells to further validate the molecular mechanisms of CMD‐BHQ3‐PTL/DOX@RBCm (Figure S9A, Supporting Information). This evidence concerns the gene SOX9 and neoplasm.